Mirum Pharmaceuticals, Inc. MIRM
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases.
We have three approved medicines: LIVMARLI® (maralixibat) ("Livmarli"), CHOLBAM® (cholic acid) capsules ("Cholbam"), and CTEXLI® (chenodiol) tablets ("Ctexli").
Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter ("IBAT") inhibitor ("IBATi") that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome ("ALGS") in the United States ("U.S."), the European Union ("EU") and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis ("PFIC") in the U.S., Canada and Japan and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S., Canada and certain countries in Europe through our specialized and focused commercial team. We have also entered into license and distribution agreements with several rare disease companies for the commercialization of Livmarli in additional countries. We are also seeking to add to the approved indications for Livmarli by conducting the EXPAND study in settings of cholestatic pruritus due to other rare conditions.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 | — | — | — |
| SG&A | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M | $22.7M | $11.8M | — | — |
| Total operating expenses | $543.4M | $424.5M | $295.5M | $208.3M | $192.6M | $104.3M | $54.7M | — | — |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M | -$104.3M | -$54.7M | — | — |
| Interest expense | $14.4M | $14.3M | $15.1M | $16.0M | — | — | — | — | — |
| Pre-tax income | -$21.4M | -$86.9M | -$162.4M | -$142.1M | -$84.0M | -$103.3M | -$52.5M | — | — |
| Income tax | $1.9M | $1.0M | $991.0K | $6.4M | $37.0K | $6.0K | $21.0K | — | — |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M | -$103.3M | -$52.6M | — | — |
| EPS, basic | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | — | — | — | — |
| EPS, diluted | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -4.58 | — | — |
| Shares, diluted (wtd. avg.) | $50.2M | $47.5M | $40.9M | $34.0M | $30.3M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $296.7M | $222.5M | $286.3M | $28.0M | $31.3M | $142.1M | $12.0M | $52.0M | — |
| Short-term investments | $86.6M | $57.8M | $0 | $123.7M | $125.2M | $89.7M | $104.7M | — | — |
| Receivables | $123.3M | $78.3M | $68.0M | $24.0M | $3.3M | $0 | — | — | — |
| Inventory | $24.9M | $22.4M | $22.3M | $5.6M | $1.5M | $0 | — | — | — |
| Total current assets | $549.7M | $392.8M | $387.5M | $190.2M | $166.6M | $236.3M | $119.4M | $52.0M | — |
| Property, plant and equipment | $1.9M | $1.1M | $706.0K | $914.0K | $981.0K | $1.3M | $1.4M | $0 | — |
| Other intangibles | $260.9M | $249.8M | $252.9M | $59.0M | $18.7M | — | — | — | — |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M | $240.9M | $146.7M | $52.0M | — |
| Accounts payable | $9.6M | $14.6M | $7.4M | $8.7M | $9.2M | $3.2M | $3.4M | $269.0K | — |
| Total current liabilities | $205.8M | $126.6M | $87.1M | $64.7M | $42.6M | $18.5M | $13.1M | $2.4M | — |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M | $68.8M | $16.4M | $2.4M | — |
| Retained earnings | -$667.5M | -$644.2M | -$556.2M | -$392.8M | -$257.2M | -$173.2M | -$69.9M | -$17.3M | — |
| Total equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M | $172.1M | $130.3M | -$17.3M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M | -$89.1M | -$39.4M | — | — |
| Depreciation and amortisation | $24.2M | $23.6M | $10.8M | $3.2M | $595.0K | $305.0K | $139.0K | — | — |
| Stock-based compensation | $71.4M | $48.4M | $35.0M | $27.0M | $23.1M | $12.6M | $6.1M | — | — |
| Capital expenditure | $954.0K | $993.0K | $109.0K | $278.0K | $24.0K | $225.0K | $281.0K | — | — |
| Investing cash flow | -$24.0M | -$90.1M | -$107.2M | $7.7M | $48.5M | $37.9M | -$127.8M | — | — |
| Financing cash flow | $40.1M | $17.7M | $336.6M | $109.1M | $73.5M | $181.3M | $127.2M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001759425-26-000027.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |